X
Access Company Profiles

Get business overview, business operations details specific to this market, products and services, latest developments and more...

Business Email

Select Companies

 

Oncology Based In-Vivo CRO Companies

This report lists the top Oncology Based In-Vivo CRO companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Oncology Based In-Vivo CRO industry.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Oncology Based In-Vivo CRO Top Companies

  1. Crown Bioscience Inc.

  2. Charles River Laboratories, Inc.

  3. ICON plc

  4. Taconic Biosciences, Inc.

  5. Covance Inc.

*Disclaimer: Top companies sorted in no particular order

 Oncology Based In-Vivo CRO Market Major Players

Oncology Based In-Vivo CRO Market Concentration

Oncology Based In-Vivo CRO Market Concentration

Oncology Based In-Vivo CRO Company List

                            • Champions Oncology Inc.

                            • Charles River Laboratory Inc.

                            • Crown Bioscience Inc.

                            • Eurofins Scientific

                            • EVOTEC

                            • ICON Plc

                            • Labcorp Drug Development (Laboratory Corporation of America Holdings)

                            • Living Tumor Laboratory

                            • Taconic Biosciences Inc.

                            • The Jackson Laboratory

                            • Wuxi AppTec.

                            • XenTech


                        Specific to Oncology Based In-Vivo CRO Market
                        Need More Details On Market Players And Competitors?
                        Download PDF

                        Oncology Based In-Vivo CRO Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)